Exciting News!
We are thrilled to announce that our patent application has been granted by the Brazilian Patent Office! The granted patent, BR112014000324-6, is titled “Sugar-alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof.”
It took an awfully long time to get this patent approved, but we are delighted that it has finally been allowed. This achievement marks another important milestone in our mission to improve how medicines reach their targets. It also adds to our growing IP portfolio of 13 patents and demonstrates our continued leadership in bioconjugation technology.
A special thank you to our research team and our IP counsel partners for their dedication and efforts in making this success possible.
About CellMosaic, Inc.
CellMosaic® Inc. is a Massachusetts-based biotech company dedicated to creating high-quality, innovative, and advanced bioconjugates. Bioconjugates are used broadly as research tools, diagnostic reagents, and a novel modality for drugs. Due to the complexities of the bioconjugation process and requirement of techniques and knowledge across multidisciplinary fields, not many companies are competent to offer high-quality bioconjugation services and to provide high-quality bioconjugates. CellMosaic was established in 2008 to fill this gap and has since spent a lot of research effort on developing innovative linkers, crosslinking technologies, and advanced bioconjugation processes. CellMosaic’s current business is organized into four units: 1) Reagent/kit business commercializing bioconjugate reagents and personalized bioconjugation kits (PerKit®) based on CellMosaic’s advanced bioconjugation processes − many of these PerKits™ are for preparation of advanced bioconjugates by the customer, such as antibody drug conjugates (ADCs), antibody oligo conjugates (AOCs), and single labeled bioconjugates; 2) Custom conjugation services for research bioconjugates; 3) Contract bioconjugate manufacturing focusing on process development, scale-up, and GLP/GMP manufacturing, and 4) AqT® ADC development focusing on licensing and manufacturing next-generation ADCs using super-hydrophilic and high loading AqT® linkers. These four business units complement each other and form an integrated bioconjugation workflow from ideation to commercialization.
About AqueaTether™ (AqT™) Therapeutics
AqT™ Therapeutics, a division of CellMosaic established in 2016, focuses on the discovery and development of novel hybrid drug entities that beyond the conventional drug classes by leveraging AqT™ conjugation and delivery platform technologies. AqT™ drug delivery technologies are engineered to efficiently load and conjugate highly hydrophobic small molecule drugs, such as antibody-drug conjugates (ADCs), or to modify unstable large biologics like antibodies—creating safer, more effective cancer therapies. We collaborate closely with our partners to advance their programs. For more information about AqT™-based bioconjugate drugs, please visit: www.aqttherapeutics.com.